Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Nabiximols · GW-1000, GW 1000-02

Other · Agonist of cannabinoid receptor 1 (CNR1) · developed by Jazz Pharmaceuticals

Phase 2 Most advanced trial
JAZZ Developer

What is Nabiximols?

Nabiximols is an oromucosal spray containing standardized cannabinoids including tetrahydrocannabinol (THC) and cannabidiol (CBD) from cannabis plant varieties. It acts as an agonist at cannabinoid receptor 1 (CB1) in the central nervous system, producing analgesic and anticonvulsive effects. It is studied in glioblastoma and recurrent brain tumors.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
GW-1000, GW 1000-02, Sativex
Drug type
Other
Targets
cannabinoid receptor 1 (CNR1)
Mechanism
Agonist of cannabinoid receptor 1 (CNR1)
Pathways
analgesia, anticonvulsive effects
Therapy area
Oncology
Developer
Jazz Pharmaceuticals (JAZZ)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
K4H93P747O

Conditions studied

Brain TumorBrain Tumor, RecurrentCannabisGlioblastoma

Other drugs acting on CNR1

Dronabinol FDA approved

More from Jazz Pharmaceuticals

Asparaginase Erwinia chrysanthemi FDA approved Calcium, Magnesium, Potassium, And Sodium Oxybates FDA approved Daunorubicin And Cytarabine Liposome FDA approved Defibrotide FDA approved Lurbinectedin FDA approved Zanidatamab FDA approved CBD-OS Phase 3 Flezurafenib Phase 1 JZP269 Phase 1 JZP926 Phase 2/3 ONC206 Phase 2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the JAZZ page.

Follow JAZZ, the company behind Nabiximols

See JAZZ's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

JAZZ catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.